NASDAQ:OVID Ovid Therapeutics - OVID Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.43 -0.02 (-0.82%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.43▼$2.4850-Day Range$1.66▼$2.5352-Week Range$1.40▼$3.55Volume44,219 shsAverage Volume61,728 shsMarket Capitalization$171.23 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Ovid Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside2.9% Upside$2.50 Price TargetShort InterestHealthy0.39% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.79) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.64 out of 5 starsMedical Sector865th out of 1,028 stocksPharmaceutical Preparations Industry428th out of 501 stocks 1.0 Analyst's Opinion Consensus RatingOvid Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, Ovid Therapeutics has a forecasted upside of 2.9% from its current price of $2.43.Amount of Analyst CoverageOvid Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.39% of the float of Ovid Therapeutics has been sold short.Short Interest Ratio / Days to CoverOvid Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ovid Therapeutics has recently increased by 2.90%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOvid Therapeutics does not currently pay a dividend.Dividend GrowthOvid Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOvid Therapeutics has received a 71.15% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for Epilepsy or seizures" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Ovid Therapeutics is -0.85. Previous Next N/A News and Social Media Coverage Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ovid Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.70% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.52% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Ovid Therapeutics are expected to grow in the coming year, from ($0.79) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ovid Therapeutics is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ovid Therapeutics is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOvid Therapeutics has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ovid Therapeutics (NASDAQ:OVID) StockOvid Therapeutics, Inc. is a biopharmaceutical company, engaged in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.Read More Receive OVID Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OVID Stock News HeadlinesJanuary 5, 2023 | finance.yahoo.comOvid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 TrialJanuary 4, 2023 | ca.finance.yahoo.comBelharra Therapeutics Debuts With $130 Million in FundingFebruary 5, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…December 2, 2022 | finance.yahoo.comOvid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)November 14, 2022 | finance.yahoo.comCancer Gene Therapy Market Report 2022: High Growth in the Pharmaceutical Industry Driving SectorNovember 13, 2022 | marketwatch.comDravet Syndrome Therapeutics Market 2023: Global Research by Size, Share, Growth Trends, Manufacturers, and Regional Demand Scope Forecast to 2029November 8, 2022 | finance.yahoo.comOvid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate HighlightsOctober 18, 2022 | finance.yahoo.comOvid Therapeutics (NASDAQ:OVID) shareholders have endured a 77% loss from investing in the stock five years agoFebruary 5, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…September 27, 2022 | finance.yahoo.comOvid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare ConferenceSeptember 7, 2022 | finance.yahoo.comOvid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 7, 2022 | finance.yahoo.comOvid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 18, 2022 | seekingalpha.comOvid Therapeutics (OVID) Corporate Presentation - SlideshowAugust 14, 2022 | finance.yahoo.comIs Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?August 9, 2022 | finance.yahoo.comOvid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate HighlightsAugust 2, 2022 | msn.comOvid-Elsie Area Schools Superintendent Ryan Cunningham is retiring Aug. 31July 28, 2022 | bizjournals.comThe Petri Dish: FDA agrees to review Biogen's ALS drug despite failed trialJuly 25, 2022 | finance.yahoo.comFlare Therapeutics Appoints Amit Rakhit, M.D. as President and Chief Executive OfficerJuly 3, 2022 | seekingalpha.comREAL,COMM and OVID among after hour moversJune 10, 2022 | finance.yahoo.comWe Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth CarefullyJune 6, 2022 | finance.yahoo.comOvid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline ConferenceMay 11, 2022 | finance.yahoo.comInvestors in Ovid Therapeutics (NASDAQ:OVID) have unfortunately lost 80% over the last five yearsMay 10, 2022 | benzinga.comOvid Therapeutics: Q1 Earnings InsightsMay 10, 2022 | finance.yahoo.comOvid Therapeutics Reports First Quarter 2022 Financial Results and Corporate HighlightsMay 4, 2022 | finance.yahoo.com3 Biotech Stocks Under $10 to Add to Your Buy ListMarch 21, 2022 | ca.finance.yahoo.comMarinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsMarch 15, 2022 | seekingalpha.comOvid Therapeutics GAAP EPS of -$0.38 misses by $0.22See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OVID Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OVID Company Calendar Last Earnings11/08/2022Today2/04/2023Next Earnings (Estimated)3/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OVID CUSIPN/A CIK1636651 Webwww.ovidrx.com Phone(646) 661-7661FaxN/AEmployees57Year Founded2014Price Target and Rating Average Stock Price Forecast$2.50 High Stock Price Forecast$2.50 Low Stock Price Forecast$2.50 Forecasted Upside/Downside+2.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$122.83 million Net MarginsN/A Pretax Margin-4,736.61% Return on Equity-42.99% Return on Assets-37.73% Debt Debt-to-Equity Ratio0.11 Current Ratio20.87 Quick Ratio20.87 Sales & Book Value Annual Sales$1.46 million Price / Sales117.57 Cash Flow$1.79 per share Price / Cash Flow1.36 Book Value$2.64 per share Price / Book0.92Miscellaneous Outstanding Shares70,467,000Free Float62,927,000Market Cap$171.23 million OptionableNot Optionable Beta1.15 Social Links Key ExecutivesJeremy Max LevinChairman, President & Chief Executive OfficerJason TardioChief Operating OfficerJeffrey A. RonaChief Financial & Business OfficerClaude NicaiseHead-Research & DevelopmentJulia TsaiSenior VP-Clinical Development & Medical AffairsKey CompetitorsShattuck LabsNASDAQ:STTKImmutepNASDAQ:IMMPXeris BiopharmaNASDAQ:XERSLiminal BioSciencesNASDAQ:LMNLCytomX TherapeuticsNASDAQ:CTMXView All CompetitorsInsiders & InstitutionsBalyasny Asset Management LLCBought 31,938 shares on 11/16/2022Ownership: 0.045%Vanguard Group Inc.Bought 45,500 shares on 11/15/2022Ownership: 3.662%BlackRock Inc.Sold 17,466 shares on 11/15/2022Ownership: 1.643%Rubric Capital Management LPBought 1,633,594 shares on 11/14/2022Ownership: 6.409%Tower Research Capital LLC TRC Bought 14,062 shares on 11/10/2022Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions OVID Stock - Frequently Asked Questions Should I buy or sell Ovid Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OVID shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares. View OVID analyst ratings or view top-rated stocks. What is Ovid Therapeutics' stock price forecast for 2023? 1 analysts have issued 12 month target prices for Ovid Therapeutics' stock. Their OVID share price forecasts range from $2.50 to $2.50. On average, they expect the company's share price to reach $2.50 in the next year. This suggests a possible upside of 2.9% from the stock's current price. View analysts price targets for OVID or view top-rated stocks among Wall Street analysts. How have OVID shares performed in 2023? Ovid Therapeutics' stock was trading at $1.86 at the start of the year. Since then, OVID shares have increased by 30.6% and is now trading at $2.43. View the best growth stocks for 2023 here. When is Ovid Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023. View our OVID earnings forecast. How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics Inc. (NASDAQ:OVID) announced its earnings results on Tuesday, November, 8th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.01 million for the quarter. What other stocks do shareholders of Ovid Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX). When did Ovid Therapeutics IPO? (OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers. What is Ovid Therapeutics' stock symbol? Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID." Who are Ovid Therapeutics' major shareholders? Ovid Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amit Rakhit, Jason Tardio and Jeremy M Levin. View institutional ownership trends. How do I buy shares of Ovid Therapeutics? Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ovid Therapeutics' stock price today? One share of OVID stock can currently be purchased for approximately $2.43. How much money does Ovid Therapeutics make? Ovid Therapeutics (NASDAQ:OVID) has a market capitalization of $171.23 million and generates $1.46 million in revenue each year. The company earns $122.83 million in net income (profit) each year or ($0.99) on an earnings per share basis. How can I contact Ovid Therapeutics? Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The official website for the company is www.ovidrx.com. The company can be reached via phone at (646) 661-7661 or via email at investors@ovidrx.com. This page (NASDAQ:OVID) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.